A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in high-impact areas.

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

The Johnson & Johnson JNJ stock has risen 4.4% in six months, adding more than $15 billion to its market value. J&J faces ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated ...

There was little difference between icotrokinra and placebo on safety, with 49.3% of those on the IL-23 inhibitor and 49.1% of the placebo group reporting a treatment-emergent adverse event (TEAE ...

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting.

A high-level overview of Protagonist Therapeutics, Inc. (PTGX) stock. View (PTGX) real-time stock price, chart, news, analysis, analyst reviews and more.

J&J says oral IL-23 inhibitor JNJ-2113 shows a durable effect in psoriasis, making it a potential companion to its injectable Tremfya.

Infectious Diseases in Children | Find pediatrics news articles, videos, blogs, books, Continuing Medical Education (CME), meeting coverage, and journal articles from the #1 online source for ...

Find allergy and asthma news articles, videos, blogs, books, Continuing Medical Education (CME), meeting coverage, and journal articles.